CD39

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, February 28, 2024
Active, VSIG4, MSS, National Cancer Institute, Society, Sensei, Lung cancer, Patient, Immunotherapy, Trial of the century, Head, Neoplasm, VISTA, SITC, MBA, Annual general meeting, Therapy, Histology, Biology, NSCLC, ESMO, Kinetics, CRC, PD-1, Conference, Safety, Cemiplimab, Pharmacokinetics, CRADA, CD39, IND, Colorectal cancer, Translation, NCI, Aes, Part-time, FDA, Research and development, Administration, KOL, Cancer, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases

Retrieved on: 
Tuesday, February 13, 2024
Research, Neurology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Transfer, Spleen, Coya, Inflammation, COYA, Nebraska Medicine, Technology transfer, GM-CSF, University, Therapy, Phenotype, Patent, Patient, Gendelman, CD39, Mouse, Immune system, Pharmaceutical industry

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance regulatory T cell (Treg) function, has expanded and strengthened its patent estate beyond COYA 302, which is a combination of COYA 301 with CTLA-4 Ig.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance regulatory T cell (Treg) function, has expanded and strengthened its patent estate beyond COYA 302, which is a combination of COYA 301 with CTLA-4 Ig.
  • UNeMed will receive payments upon achievement of certain milestones and will be eligible to receive tiered low single-digit royalty on net sales.
  • This included a 4-to-6-fold higher expression of Tregs in mice treated with the combination compared to treatments with either cytokine alone.
  • Coya’s foundation and progress in low-dose IL-2 research makes them an ideal company to leverage our findings to date.”

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Retrieved on: 
Thursday, January 4, 2024
Biology, Sensei, Lung cancer, CD28, CRC, Neoplasm, Tumor microenvironment, Biotechnology, IND, DLT, FDA, VSIG4, CMO, Research, Colorectal cancer, MSS, Physician, Cancer, Pharmacokinetics, CD39, Head, Novartis, Exelixis, Part-time, Histology, VISTA, American College, Genentech, Internal medicine, Oncology, Patient, Safety, Therapy, NSCLC, Pharmaceutical industry

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.

Key Points: 
  • BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.
  • In the monotherapy dose escalation arm, patients have cleared all planned dosing cohorts of 0.3, 1, 3, 10 and 15 mg/kg.
  • Anticipated milestones for the SNS-101 Phase 1/2 clinical trial include:
    Sensei announces that Ron Weitzman, M.D., F.A.C.P., has joined Sensei as part-time Chief Medical Officer.
  • As a result, Sensei will pause IND-enabling work on its preclinical-stage TMAb programs, including SNS-102 (VSIG4), SNS-103 (CD39) and SNS-201 (VISTAxCD28).

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
VISTA, Research, Insurance, Research and development, The Year's Best Science Fiction: Twenty-Seventh Annual Collection, Northwest Biotherapeutics, ESMO, CD28, Therapy, Society for Immunotherapy of Cancer, VSIG4, Active, Safety, Conference, Translation, MBA, R, Protein, Pharmacokinetics, SITC, Immunotherapy, Sensei, Neoplasm, CD39, Cytokine release syndrome, Annual general meeting, Kinetics, CET, Tumor microenvironment, Society, Cancer, European Society for Medical Oncology, Patient, Administration, MS, Toxicity, Pharmaceutical industry, Vaccine, Cryptocurrency, Antibody, Science, Survival

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2023, and provided recent business updates.

Key Points: 
  • On October 23, 2023, Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.9 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $7.1 million for the quarter ended September 30, 2023, compared to $13.4 million for the quarter ended September 30, 2022.

Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Sunday, November 5, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neoplasm, Trial of the century, NSCLC, B cell, CD8, NKG2C, SITC, LILRB1, Ligation, CD39, NK, Cancer, Annual general meeting, Tumor microenvironment, Safety, Lymphocyte, TME, Patient, MPE, Vaccine, Medical imaging

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014.

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014.
  • CD39-targeted TGFβ “trap” is thus more likely to effectively inhibit tumor progression.
  • Our NKG2A/NKG2C dual targeting antibody ES015-2 can inhibit NKG2A function yet promoting NKG2C action, leading to superior anti-tumor response.
  • ES008-a synergizes with CD47/SIRPα inhibitors in enhancing macrophage phagocytosis of tumor cells.

Cellenkos® Announces Oral Presentation and Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

Retrieved on: 
Monday, November 6, 2023
Primary myelofibrosis, Life, Bone marrow, Inflammation, CXCR4, Ruxolitinib, Cell, CXCR5, Society, ASH, Suboptimal health, CD39, Anemia, Blood transfusion, Exposition, Safety, CD73, CXCL12, Patient, CD62L, Pharmaceutical industry, Rare-earth element, Regulatory T cell

Oral presentation highlights the resolving of inflammation and superior homing to bone marrow of CXCR4-enriched T regulatory cells.

Key Points: 
  • Oral presentation highlights the resolving of inflammation and superior homing to bone marrow of CXCR4-enriched T regulatory cells.
  • HOUSTON, Nov. 6, 2023 /PRNewswire/ -- Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory (Treg) cell therapies for treatment of rare inflammatory diseases and autoimmune disorders, today announces an oral presentation and poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held December 9-12, 2023, in San Diego, California.
  • This presentation has also been selected for ASH Abstract Achievement Award.
  • The poster presentation will elaborate on the results of Company's CK0804 Phase 1b trial.

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, August 3, 2023
Bispecific monoclonal antibody, KOL, Sensei, Therapy, Biochemistry, Neoplasm, Drug discovery, Clinical trial, CRADA, Cancer, Lead, Northwest Biotherapeutics, Research, Antibody, Washington University in St. Louis, Bangladesh Technical Education Board, National Cancer Institute, Patient, Pathology, Administration, CD39, VISTA, VSIG4, Research and development, Immunology, R, FDA, NCI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Vaccine, Fine chemical, Cryptocurrency, Development

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2023, and provided recent business updates.

Key Points: 
  • “The second quarter of 2023 was momentous for Sensei as we moved expeditiously from the FDA’s clearance of our SNS-101 trial in April to the enrollment of six patients by the end of July.
  • Recent updates for SNS-101 include:
    An Investigational New Drug (IND) application for SNS-101 was cleared by the U.S. Food and Drug Administration (FDA) in April 2023.
  • On June 1, 2023, Sensei reported the first patient dosed in the dose escalation portion of the SNS-101 multi-center Phase 1/2 clinical trial.
  • Net Loss: Net loss was $9.4 million for the quarter ended June 30, 2023, compared to $10.5 million for the quarter ended June 30, 2022.

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
GLP, Sensei, AACR, Therapy, Food and Drug Administration, CRADA, Cancer, Clinical trial, Pharmacokinetics, American Association for Cancer Research, Northwest Biotherapeutics, Tumor microenvironment, Bangladesh Technical Education Board, Trial of the century, National Cancer Institute, Investigational New Drug, Patient, Administration, CD39, VISTA, VSIG4, Research and development, R, Research, FDA, NCI, Kinetics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Vaccine, Fine chemical, Cryptocurrency

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2023, and provided recent business updates.

Key Points: 
  • Sensei expects to begin clinical trial enrollment and commence patient dosing at a starting dose of 0.3 mg/kg in mid-2023.
  • SNS-103: In April 2023, Sensei presented new preclinical data on SNS-103 at the American Association for Cancer Research (AACR) Annual Meeting.
  • Research and Development (R&D) Expenses: R&D expenses were $5.2 million for the quarter ended March 31, 2023, compared to $7.5 million for the quarter ended March 31, 2022.
  • Net Loss: Net loss was $10.2 million for the quarter ended March 31, 2023, compared to $12.4 million for the quarter ended March 31, 2022.

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Tuesday, April 18, 2023
Sensei, AACR, Therapy, Neoplasm, ATP, Cancer, American Association for Cancer Research, Northwest Biotherapeutics, Cell, Antibody, Adenosine, Patient, CD39, Tumor microenvironment, Vaccine

BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103 program aimed at developing a conditionally active, monoclonal antibody program targeting ENTPDase1 (also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Key Points: 
  • BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103 program aimed at developing a conditionally active, monoclonal antibody program targeting ENTPDase1 (also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023.
  • “CD39 is an important target because it is the rate-limiting enzyme that creates an immunosuppressive tumor microenvironment through the production of adenosine.
  • From a panel of 83 antibodies identified and characterized for CD39 inhibition at neutral and acidic pH, Sensei has selected 8 antibodies for further optimization.
  • Sensei intends to select a lead product candidate for SNS-103 in 2023.

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

Retrieved on: 
Thursday, April 13, 2023
Injection, CD47, Biotechnology, CD19, HLA, Lymphoid leukemia, Neoplasm, Nature Communications, MHC, NSG, Cancer, Bone marrow, CAR, HIP, LAG3, Spleen, Patient, CD39, Engineering, TIGIT, Mouse, SANA, PD-1, Recurrence, IND, BLI, Safety, Vaccine

“These preclinical data highlight that our hypoimmune CAR T cells can evade immune detection, persist, and clear tumor cells both acutely and over time.

Key Points: 
  • “These preclinical data highlight that our hypoimmune CAR T cells can evade immune detection, persist, and clear tumor cells both acutely and over time.
  • HIP CAR T cell-treated mice rapidly cleared the tumor cells, demonstrating the persistence and effectiveness of the HIP CAR T cells even after three months.
  • The efficacy of HIP CAR T cells in clearing tumors was assessed in immunodeficient mice that received low, middle, and high doses of either HIP CAR T cells or unmodified allogeneic CAR T cells intravenously.
  • HIP CAR T cells and unmodified allogeneic CAR T cells similarly reduced bone marrow cancer burden.